There have been no major breakthroughs in the treatment of smallâcell lung cancer (SCLC) in recent decades. It is thus essential to explore new or adjuvant treatment options for SCLC. Resveratrol (Res) is a natural antioxidant revealed to influence the entire process of cancer development. Accordingly, the present study used the SCLC cell line H446 to explore the antitumor mechanism of Res. Cells were treated with 40 µg/ml Res with or without pretreatment with the antioxidant NâacetylâLâcysteine (NAC). H446 cell viability and apoptosis were assessed with MTT and flow cytometry, and the expression of cytochrome c and the PI3K/Akt/câMyc pathway and the nuclear translocation of apoptosis inducing factor (AIF) were assessed by western blotting. In addition, the changes in ROS content and mitochondrial membrane potential were determined. The results revealed that Res inhibited H446 cell viability and induced apoptosis, increased cytochrome c expression, inhibited the expression of PI3K/Akt/câMyc signaling pathway components, and promoted the translocation of AIF from the cytoplasm to the nucleus in H446 cells. However, NAC pretreatment reversed these changes to various extents. The results of the present study indicated that Res may inhibit the viability and promote the apoptosis of human SCLC H446 cells through the PI3K/Akt/câMyc pathway and that oxidative stress and mitochondrial membrane potential depolarization may be involved in the aforementioned processes.
Resveratrol inhibits viability and induces apoptosis in the smallâcell lung cancer H446 cell line via the PI3K/Akt/câMyc pathway.
白藜芦醇通过 PI3K/Akt/c-Myc 通路抑制小细胞肺癌 H446 细胞系的活力并诱导其凋亡
阅读:5
作者:Li Wangping, Li Chunmei, Ma Lijie, Jin Faguang
| 期刊: | Oncology Reports | 影响因子: | 3.900 |
| 时间: | 2020 | 起止号: | 2020 Nov;44(5):1821-1830 |
| doi: | 10.3892/or.2020.7747 | 靶点: | H4 |
| 研究方向: | 细胞生物学 | 疾病类型: | 肺癌 |
| 信号通路: | PI3K/Akt | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
